愛齊科技 (ALGN) 2021 Q2 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Greetings, and welcome to the Align Technology, Inc. Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.

    各位好,歡迎參加 Align Technology, Inc.電話會議。(接線員指示) 提醒各位,本次會議將被錄音。

  • I would now like to turn the conference over to your host, Shirley Stacy, VP, Corporate Communications and Investor Relations.

    現在我想把會議交給本次主持人,企業傳播與投資人關係副總裁 Shirley Stacy。

  • Shirley Stacy - VP of Corporate Communications & IR

    Shirley Stacy - VP of Corporate Communications & IR

  • Good afternoon, and thank you for joining us. I'm Shirley Stacy, Vice President of Corporate Communications and Investor Relations. Joining me for today's call is Joe Hogan, President and CEO; and John Morici, CFO. We issued second quarter 2021 financial results today via GlobeNewswire, which is available on our website at investor.aligntech.com.

    各位下午好,感謝各位加入我們。我是 Shirley Stacy,企業傳播與投資人關係副總裁。今天與我一同參與電話會議的有總裁暨執行長 Joe Hogan,以及財務長 John Morici。我們已於今日透過 GlobeNewswire 發布 2021 年第二季財務結果,相關內容可於我們網站 investor.aligntech.com 取得。

  • Today's conference call is being audio webcast and will be archived on our website for approximately 1 month. A telephone replay will be available by approximately 5:30 p.m. Eastern Time through 5:30 p.m. Eastern Time on August 11. To access the telephone replay, domestic callers should dial 877-660-6853 with conference number 13720779 followed by #. International callers should dial 201-612-7415 with the same conference number.

    今天的電話會議將以音訊方式進行網路直播,並將在我們網站上封存約 1 個月。電話重播預計將於美東時間下午 5:30 左右提供,並可使用至 8 月 11 日美東時間下午 5:30。如需收聽電話重播,美國境內來電者請撥 877-660-6853,會議號碼 13720779,然後按 #。國際來電者請撥 201-612-7415,並使用相同的會議號碼。

  • As a reminder, the information provided and discussed today will include forward-looking statements, including statements about Align's future events and product outlook. These forward-looking statements are only predictions and involve risks and uncertainties that are described in more detail in our most recent periodic reports filed with the Securities and Exchange Commission available on our website and at sec.gov. Actual results may vary significantly, and Align expressly assumes no obligation to update any forward-looking statements. We've posted historical financial statements, including the corresponding reconciliations, including our GAAP to non-GAAP reconciliation, if applicable, and our second quarter 2021 conference call slides on our website under quarterly results. Please refer to these files for more detailed information.

    提醒各位,今天提供與討論的資訊將包含前瞻性陳述,包括關於 Align 未來事件及產品展望的陳述。這些前瞻性陳述僅為預測,並涉及風險與不確定性;相關內容在我們最近期向美國證券交易委員會提交的定期報告中有更詳細的說明,該等報告可於我們網站及 sec.gov 查閱。實際結果可能存在重大差異,Align 明確表示不承擔更新任何前瞻性陳述之義務。我們已在網站「季度業績」專區張貼歷史財務報表及相應調節表,包括(如適用)GAAP 與非 GAAP 的調節,以及 2021 年第二季電話會議簡報。請參閱上述檔案以取得更詳細資訊。

  • With that, I'd like to turn the call over to Align Technology's President and CEO, Joe Hogan. Joe?

    接下來,我想把電話會議交給 Align Technology 總裁暨執行長 Joe Hogan。Joe?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Thanks, Shirley. Good afternoon, and thanks for joining us. On our call today, I'll provide some highlights from the second quarter then briefly discuss the performance of our 2 operating segments, System and Services and Clear Aligners. John will provide more detail on our financial results and discuss our outlook. Following that, I'll come back and summarize a few key points and open the call to questions.

    謝謝你,Shirley。各位下午好,感謝各位加入我們。在今天的電話會議中,我將先提供第二季的一些重點,接著簡要說明我們兩個營運部門——系統與服務(Systems and Services)以及透明牙套(Clear Aligners)的表現。John 將更詳細說明我們的財務結果並討論展望。之後我會回來總結幾個關鍵重點,並開放提問。

  • I'm pleased to report our first $1 billion revenue quarter with record volumes reflecting continued momentum from both Clear Aligners and Systems and Services. For Q2, Systems and Services revenues reflect strong growth across all regions and the strategic value of the iTero business with continued adoption of the iTero Element 5D Plus Series of next-generation scanners and imaging systems, which launched in February. Increasingly, doctors are seeing the strategic impact and value of iTero scanners in their practices. In addition to its role in Invisalign case submissions, it's true -- it's a true workhorse and digital enabler in every type of practice and across every type of orthodontic and restorative workflow.

    我很高興報告,我們首次達成單季營收 10 億美元,出貨量創新高,反映透明牙套與系統與服務兩大業務持續的成長動能。就第二季而言,系統與服務營收反映各區域的強勁成長,以及 iTero 業務的策略價值;自 2 月推出以來,新一代掃描與影像系統 iTero Element 5D Plus 系列持續被採用。醫師們愈來愈能在其診所中看見 iTero 掃描儀的策略影響與價值。除了在 Invisalign 病例提交中的角色之外,確實——它是各類型診所中的真正主力工具與數位化推動者,適用於各種矯正與修復的工作流程。

  • Q2 sequential Clear Aligner volumes were primarily driven by strength in both adult and teen market segments and across customer channels and regions, especially from the Americas and EMEA regions, reflecting the expanding opportunity for Invisalign treatment among adults globally as well as the underlying orthodontic market as we continue to build awareness of the Invisalign brand and drive utilization among teens and younger patients.

    第二季透明牙套出貨量的季增,主要由成人與青少年兩大市場區隔的強勁需求所帶動,且涵蓋各客戶通路與各地區,尤其是美洲與 EMEA 地區;這反映全球成人 Invisalign 治療機會的擴大,以及在我們持續提升 Invisalign 品牌認知、並推動青少年與更年輕患者使用率之下,整體矯正市場的基本面。

  • For Q2 '21, Invisalign clear aligner volumes for teens were up 9.5% sequentially, 156% year-over-year to 181,000 teens, representing 1/3 of total cases shipped, with strong growth from North America and EMEA orthodontists. During the quarter, we hosted several teen-focused peer-to-peer events designed to build clinical confidence in teen treatment and highlight the teen digital treatment journey with Invisalign treatment. The recent APAC virtual symposium featured leading providers focusing on clinical excellence with teen treatment, and North America hosted the Invisalign Teen Forum: Virtual Edition for Invisalign doctors, bringing together clinical speakers, digital industry experts and teen patient panelists to share their insights. In May, Align focused on the Align Digital Platform at the 2021 AAO annual session, featuring a dynamic virtual lineup of Invisalign doctors describing how they have grown their practices through adoption of digital technology.

    就 2021 年第二季而言,Invisalign 青少年透明牙套出貨量季增 9.5%,年增 156% 至 181,000 例青少年病例,約占總出貨病例的 1/3;其中北美與 EMEA 地區的矯正醫師帶來強勁成長。本季期間,我們舉辦了多場以青少年為主題的同儕交流活動(peer-to-peer),旨在建立醫師對青少年治療的臨床信心,並凸顯 Invisalign 青少年數位化治療旅程。近期的 APAC 線上研討會邀請領先的醫療提供者,聚焦於青少年治療的臨床卓越;北美則為 Invisalign 醫師舉辦 Invisalign Teen Forum:Virtual Edition,匯集臨床講者、數位產業專家與青少年患者座談成員分享見解。5 月,Align 在 2021 年 AAO 年會上聚焦 Align 數位平台(Align Digital Platform),並安排一系列精彩的線上內容,由 Invisalign 醫師分享其如何透過採用數位技術來成長其診所。

  • Our Q2 results also reflect the positive impact of our investments in consumer marketing, generating billions of impressions and 33% year-over-year increase in leads for Invisalign doctors. During the quarter, we launched the next phase of our Mom/Teen multitouch campaign as well as the new "Invis is a powerful thing" campaign designed to engage teens and young adults. We also deepened our partnership with influencers like Charli D’Amelio, with the first limited-edition aligner case as part of our new e-commerce initiative featuring custom cases, cleaning and oral care products as well as accessories like Invisalign Stickables, all of which are available on invisalign.com. These and other consumer initiatives are important in supporting doctors' practices, especially through the busy summer teen season and beyond. They also build out our investments in digital technology and innovation that are the foundation of the Align Digital Platform, including integrated digital workflows and virtual tools designed to improve clinical confidence, treatment, efficiency and patient outcomes.

    我們第二季的結果也反映了我們在消費者行銷投資的正面效益,帶來數十億次曝光,並使 Invisalign 醫師的潛在客戶(leads)年增 33%。本季期間,我們推出 Mom/Teen 多觸點行銷活動的下一階段,以及全新的「Invis is a powerful thing」活動,旨在吸引青少年與年輕成人。我們也深化與 Charli D’Amelio 等網紅的合作,推出首款限量版牙套收納盒,作為新電商計畫的一部分;該計畫提供客製化收納盒、清潔與口腔護理產品,以及如 Invisalign Stickables 等配件,皆可於 invisalign.com 購買。這些及其他消費者計畫對於支持醫師診所營運非常重要,尤其是在繁忙的暑期青少年旺季及其後。同時,這些計畫也延伸我們在數位技術與創新方面的投資,這些投資是 Align 數位平台的基礎,包括整合式數位工作流程與虛擬工具,旨在提升臨床信心、治療效率與患者治療成果。

  • A year ago, we released Invisalign Virtual Appointment and Invisalign Virtual Care tools within our My Invisalign app in response to the global pandemic to enable Invisalign doctors to provide continuity of care for their patients. Today, Invisalign Virtual Care is available globally in 60 markets, and the My Invisalign app has been downloaded 1 million times with Invisalign patients worldwide. It was recently recognized as the Best Virtual Care Platform by the MedTech Breakthrough Awards program and as a Digital Innovation of the Year by Healthcare Asia Medtech Awards. As part of the Invisalign Virtual Care, patients use My Invisalign app to stay engaged with their treatment and convey progress photos to their doctor, fostering 2-way communications with a doctor through their Invisalign treatment journey.

    一年前,為因應全球疫情,我們在 My Invisalign 應用程式中推出 Invisalign Virtual Appointment 與 Invisalign Virtual Care 工具,使 Invisalign 醫師能為其患者提供不中斷的照護。目前,Invisalign Virtual Care 已在全球 60 個市場提供,而 My Invisalign 應用程式已在全球 Invisalign 患者中累計下載 100 萬次。該方案近期獲 MedTech Breakthrough Awards 評選為最佳虛擬照護平台(Best Virtual Care Platform),並獲 Healthcare Asia Medtech Awards 評選為年度數位創新(Digital Innovation of the Year)。作為 Invisalign Virtual Care 的一部分,患者使用 My Invisalign 應用程式持續參與其治療,並向醫師傳送進度照片,促進在 Invisalign 治療旅程中的醫病雙向溝通。

  • Now let's turn to the specifics around our second quarter results, starting with the Americas. For the Americas region, Q2 was another strong quarter, with Invisalign case volumes up 11% sequentially and 261% year-over-year, reflecting growth across the region, especially in the United States and Canada, from both comprehensive and non-comprehensive products, and increased Invisalign utilization from orthodontic and GP channels. DSO utilization continues to be a strong growth driver as well, led by Heartland and Smile Docs.

    接下來我們來看第二季業績的具體細節,先從美洲地區開始。就美洲地區而言,第二季再度表現強勁,Invisalign 病例量季增 11%、年增 261%,反映整個地區的成長,尤其是美國與加拿大;成長動能來自綜合型(comprehensive)與非綜合型(non-comprehensive)產品,以及矯正與一般牙科(GP)通路中 Invisalign 使用率的提升。DSO 的使用率也持續成為強勁的成長驅動力,其中以 Heartland 與 Smile Docs 為首。

  • For international business, Q2 Invisalign case volume was up sequentially 12.7% on a year-over-year basis. International shipments were up 149%.

    就國際業務而言,第二季 Invisalign 病例量較前一季成長 12.7%,以年對年基礎計算。國際出貨量年增 149%。

  • For EMEA, Q2 volumes were up sequentially, 17% and 265% year-over-year, with broad-based growth across all markets, led by Iberia, U.K. and Italy, along with continued growth in our expansion markets. In Q2, growth in both channels was strong, with orthodontic channel growth reflecting increased Invisalign utilization and GP channel growth driven by increased Invisalign submitters. For Q2, EMEA growth also reflects adoption of the Invisalign First product, designed to treat a broad range of teeth-straightening issues in growing children from simple to complex, including crowding, spacing and narrow dental arches. Aiding in treatment engagement for those younger patients, Invisalign Stickables are innovative accessories designed exclusively for use with a patented SmartTrack material in Invisalign clear systems. Available in an array of designs, colors, shapes and themes, Invisalign Stickables are a fun way for patients to show their personal style during Invisalign treatment. During the quarter, we also hosted a successful virtual edition of GP Growth Summit attended by over 1,200 doctors from the EMEA region.

    就 EMEA 而言,第二季出貨量較前一季成長,年增分別為 17% 與 265%,所有市場皆呈現廣泛成長,主要由伊比利亞半島、英國與義大利帶動,並且我們的擴張市場也持續成長。第二季兩個通路的成長都很強勁,其中矯正通路的成長反映 Invisalign 使用量提升,而 GP(一般牙科)通路的成長則由提交 Invisalign 案例的醫師人數增加所帶動。第二季 EMEA 的成長也反映 Invisalign First 產品的採用;該產品旨在治療成長中兒童從簡單到複雜的各類牙齒矯正問題,包括擁擠、間隙與狹窄牙弓。為了提升年幼患者的治療參與度,Invisalign Stickables 是創新配件,專為搭配 Invisalign 透明系統中具專利的 SmartTrack 材料使用而設計。Invisalign Stickables 提供多種設計、顏色、形狀與主題,讓患者在 Invisalign 治療期間以有趣的方式展現個人風格。本季期間,我們也成功舉辦了 GP Growth Summit 的線上版本,來自 EMEA 地區超過 1,200 位醫師參與。

  • For APAC, Q2 volumes were up sequentially 4.8% and 50% on a year-over-year basis, reflecting growth across the region, led by Japan, China and ANZ despite new and extended COVID restrictions in several APAC markets. APAC performance reflects strength in GP channel with increased Invisalign submitters, especially in Japan which continues to deliver strong growth. During the quarter, we hosted our China Forum attended by over 1,500 doctors from private clinics, our APAC Virtual Symposium attended by 1,400 doctors, as well as the China Public Hospital Forum in June.

    就 APAC 而言,第二季出貨量較前一季成長 4.8%,年增 50%,反映整個區域的成長;儘管 APAC 多個市場面臨新增與延長的 COVID 限制,日本、中國與 ANZ 仍為主要成長動能。APAC 的表現反映 GP 通路的強勁,提交 Invisalign 案例的醫師人數增加,尤其是日本持續交出強勁成長。本季期間,我們舉辦了中國論壇,吸引超過 1,500 位來自私人診所的醫師參與;也舉辦了 APAC 線上研討會,吸引 1,400 位醫師參與;並於 6 月舉辦中國公立醫院論壇。

  • Our consumer marketing is focused on educating consumers about the Invisalign system and driving that demand for Invisalign doctor's offices, ultimately capitalizing on the massive market opportunity to transform 500 million smiles. We have provided many of our key metrics that show increased activity engagement with the Invisalign brand in our Q2 quarterly presentation slides available on aligntech.com.

    我們的消費者行銷聚焦於教育消費者了解 Invisalign 系統,並帶動對 Invisalign 醫師診所的需求,最終把握龐大的市場機會,改變 5 億個笑容。我們已在 aligntech.com 上提供第二季季度簡報投影片,其中包含多項關鍵指標,顯示消費者與 Invisalign 品牌互動參與度提升。

  • In Q2, we launched the next generation of "Invis is" multitouch campaign, driving reach and awareness with adult mom and teen consumers, yielding more than 200% growth in visitors globally to our websites and more than 82% increase in searches for an Invisalign-trained doctor. Leading with the "Invis is not your parents' braces" campaign, we connected with teens, utilizing digital media such as YouTube, Twitch and social media. We also continued with our Invisalign ChangeMakers program that celebrated and recognized teens driving change in their communities, which was covered by multiple media outlets such as Elite Daily, Refinery29, Yahoo! Unwind, Hollywood Life, SheKnows, J-14, Yahoo Finance, Parents.com, Glamour and NewBeauty, and generated more than 600 million impressions.

    第二季,我們推出新一代「Invis is」多觸點行銷活動,提升成人媽媽族群與青少年消費者的觸及與認知,使全球網站訪客成長超過 200%,並使搜尋 Invisalign 認證醫師的次數增加超過 82%。以「Invis is not your parents' braces」活動為主軸,我們透過 YouTube、Twitch 與社群媒體等數位媒體與青少年建立連結。我們也持續推動 Invisalign ChangeMakers 計畫,表揚並肯定在社區推動改變的青少年;該計畫獲 Elite Daily、Refinery29、Yahoo!Unwind、Hollywood Life、SheKnows、J-14、Yahoo Finance、Parents.com、Glamour 與 NewBeauty 等多家媒體報導,並產生超過 6 億次曝光。

  • In EMEA region, our new marketing campaign to drive engagement, "Invis is a powerful thing," went live in the U.K., Germany and France during the quarter, resulting in more than 170% year-over-year increase in unique visitors and 136% year-over-year increase in doctor locator searches. We will continue to roll out the campaign to additional markets in the region during the third quarter. We continued to expand our consumer advertising in the APAC region in Australia, Japan and China and saw more than an 800% increase in consumer engagement and 55% year-over-year increase in leads.

    在 EMEA 地區,我們用以提升互動參與的新行銷活動「Invis is a powerful thing」於本季在英國、德國與法國上線,使獨立訪客年增超過 170%,醫師搜尋定位(doctor locator)查詢次數年增 136%。我們將在第三季持續把該活動推廣至該區域更多市場。我們也持續在 APAC 地區擴大消費者廣告投放,涵蓋澳洲、日本與中國,並看到消費者互動參與度增加超過 800%,以及潛在客戶(leads)年增 55%。

  • Lastly, we continue to build strong relationship with global search and social media giants like Google, Snapchat and TikTok in order to further leverage our best-in-class consumer demand programs more effective globally. These partners recognize the power of the Invisalign brand and are helping us to amplify and gain efficiencies from our investments.

    最後,我們持續與 Google、Snapchat 與 TikTok 等全球搜尋與社群媒體巨頭建立緊密合作關係,以便在全球更有效地運用我們同級最佳的消費者需求推動方案。這些合作夥伴認可 Invisalign 品牌的力量,並協助我們放大投資效益並提升效率。

  • For our Systems and Services business, Q2 revenues were up 20% sequentially and up 214% year-over-year, reflecting strong scanner shipments and services. This represents the fourth consecutive quarter of sequential revenue growth.

    就我們的系統與服務(Systems and Services)業務而言,第二季營收較前一季成長 20%,年增 214%,反映掃描儀出貨與服務表現強勁。這是連續第四個季度營收呈現季增。

  • The iTero Element 5D Plus imaging system continues to gain traction across all regions, with strong adoption with new customers in the APAC and EMEA regions and with existing customers in the Americas region. In APAC, the iTero Element 2 intraoral scanner did well during the quarter, helping to transform digital workflows and chairside consults for doctors. During the quarter, we announced a new iTero Workflow 2.0 software and previewed auto-upload functionality in the iTero Element 5D imaging system. The iTero Workflow 2.0 software's advanced features include faster scanning, improved visualization and enhanced patient communication tools, were rolled out regionally in all markets where the iTero Element Plus imaging systems are sold. The iTero Element 5D imaging system auto-upload feature will eliminate steps and streamline Invisalign case submissions, with intraoral color scan images that can be used in place of traditional intraoral photos. The auto-upload functionality is scheduled for release during the third quarter of 2021.

    iTero Element 5D Plus 影像系統持續在各區域獲得更多採用,在 APAC 與 EMEA 地區的新客戶採用強勁,且在美洲地區的既有客戶中也有良好採用。在 APAC,iTero Element 2 口內掃描儀本季表現良好,協助醫師轉型數位工作流程與椅旁諮詢。本季期間,我們宣布推出新的 iTero Workflow 2.0 軟體,並預覽 iTero Element 5D 影像系統的自動上傳功能。iTero Workflow 2.0 軟體的進階功能包括更快的掃描速度、改善的視覺化呈現與強化的病患溝通工具,並已在所有銷售 iTero Element Plus 影像系統的市場按區域逐步推出。iTero Element 5D 影像系統的自動上傳功能將可減少步驟並簡化 Invisalign 案例提交流程,並可使用口內彩色掃描影像取代傳統口內照片。自動上傳功能預計於 2021 年第三季發布。

  • There's great symmetry between Systems and Services business with Clear Aligner business reflected in the positive correlation between the deployment of scanners and the increased utilization of Invisalign clear aligners. In terms of digital scans used for Invisalign case submissions, total digital scans in Q2 increased to 82.2% from 78.5% in Q2 last year. International scans increased to 76.2%, up from 72% in the same quarter last year. For the Americas, 86.6% of cases were submitted digitally compared to 86% a year ago. Cumulatively, over 40.1 million orthodontic scans and 8.4 million restorative scans have been performed with iTero scanners. I'm also pleased to share that Align received regulatory approval for the iTero 5D Plus Series in Japan on July 1, with a formal launch event planned for August.

    系統與服務業務與透明矯正器(Clear Aligner)業務之間具有高度協同,體現在掃描儀部署與 Invisalign 透明矯正器使用量提升之間的正向關聯。就用於 Invisalign 案例提交的數位掃描而言,第二季數位掃描占比提升至 82.2%,高於去年第二季的 78.5%。國際市場的掃描占比提升至 76.2%,高於去年同季的 72%。在美洲地區,86.6% 的案例以數位方式提交,相較一年前的 86%。累計而言,使用 iTero 掃描儀已完成超過 4,010 萬次矯正掃描與 840 萬次修復掃描。我也很高興分享,Align 已於 7 月 1 日在日本取得 iTero 5D Plus 系列的法規核准,並計畫於 8 月舉辦正式上市活動。

  • Turning to exocad. During the quarter, exocad launched the Creator Center, the new exocad one-stop shop for online and in-person educational events, with a database consisting of 35 educational webinars showcasing the highlights and add-on features of exocad's software solutions, DentalCAD Galway 3.0, exoplan 3.0 Galway. More than 2,500 users and distributors have been trained on the new software releases worldwide.

    接著談 exocad。本季期間,exocad 推出 Creator Center,這是 exocad 全新的線上與實體教育活動一站式平台;其資料庫包含 35 場教育網路研討會,展示 exocad 軟體解決方案(DentalCAD Galway 3.0、exoplan 3.0 Galway)的重點與附加功能。全球已有超過 2,500 名使用者與經銷商接受新軟體版本的培訓。

  • exocad has also expanded their market coverage with a new global OEM partner, Ivoclar Vivadent, or we call IV, one of the largest manufacturers in the dental industry. This strategic collaboration will give exocad access to thousands of new IV users worldwide, will also provide exocad users with access to production processes with removable prosthetics in the future.

    exocad 也透過新的全球 OEM 合作夥伴 Ivoclar Vivadent(我們稱為 IV)擴大市場覆蓋;IV 是牙科產業最大的製造商之一。此策略合作將使 exocad 能接觸全球數以千計的 IV 新用戶,並且未來也將讓 exocad 用戶可使用包含可摘式義齒在內的生產流程。

  • Earlier this month, exocad has released PartialCAD 3.0 Galway, its module for removable partial dental frameworks, which has new and advanced features for the design of high-quality partial dentures. This new release enhances digital CAD/CAM possibilities for exocad users and dental technicians by providing simpler design solutions for complex cases. PartialCAD 3.0 Galway provide both experts and new users with smooth, improved integration with DentalCAD, exocad's leading software for dental laboratories.

    本月稍早,exocad 發布 PartialCAD 3.0 Galway,這是其用於可摘式局部義齒支架的模組,新增先進功能以設計高品質的局部義齒。此新版本透過為複雜案例提供更簡化的設計解決方案,強化 exocad 用戶與牙科技師的數位 CAD/CAM 可能性。PartialCAD 3.0 Galway 為專家與新用戶提供順暢且改良的與 DentalCAD 的整合;DentalCAD 是 exocad 針對牙科實驗室的領先軟體。

  • Bringing the iTero and exocad businesses together makes us more viable within the GP segment and more relevant in day-to-day comprehensive dentistry for our customers. The combination of Invisalign clear aligners and iTero scanners have long provided a seamless workflow for orthodontic treatment. The integration of exocad's expertise in restorative dentistry and implantology, guided surgery and smile design takes the Align technical portfolio beyond our established footprint in orthodontics to ortho-restorative and restorative treatment and paves the way for new, cross-disciplinary workflows that span from visualization and treatment planning to lab production to chairside. exocad also broadens Align's platform reach in digital dentistry with over 200 partners and more than 40,000 licenses installed worldwide.

    將 iTero 與 exocad 兩項業務整合,使我們在一般牙科(GP)領域更具競爭力,並在客戶日常的全方位牙科診療中更具相關性。Invisalign 隱形矯正器與 iTero 掃描儀的結合,長期以來為矯正治療提供了無縫的工作流程。整合 exocad 在修復牙科與植牙學、導引式手術與微笑設計方面的專業,將 Align 的技術產品組合從我們既有的矯正版圖,延伸至正畸-修復與修復治療,並為跨領域的新工作流程鋪路,涵蓋從視覺化與治療規劃到牙技所製作,再到椅旁端的全流程。exocad 亦透過超過 200 家合作夥伴及全球安裝逾 40,000 套授權,擴大 Align 在數位牙科平台的觸及範圍。

  • With that, I'll now turn the call over to John.

    接下來,我把電話會議交給 John。

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Thanks, Joe. Let me begin by reminding everyone that for Align and many companies, Q2 2020 was significantly impacted by COVID-19 business disruptions, and comparisons of our results for Q2 2021 should be considered accordingly.

    謝謝你,Joe。我先提醒各位,對 Align 以及許多公司而言,2020 年第二季(Q2 2020)受到 COVID-19 造成的營運中斷顯著影響,因此在比較我們 2021 年第二季(Q2 2021)的業績時,應一併納入考量。

  • Now for our Q2 financial results. Total revenues for the second quarter were $1 billion, up 13% from the prior quarter and up 186.9% from the corresponding quarter a year ago.

    接著說明我們第二季的財務結果。第二季總營收為 10 億美元,較前一季成長 13%,較去年同期成長 186.9%。

  • For Clear Aligners, Q2 revenues of $841 million were up 11.6% sequentially and up 181.9% year-over-year, reflecting Invisalign volume growth in most geographies. In Q2, we shipped a record 665,600 Invisalign cases, an increase of 11.7% sequentially and 200% year-over-year. In addition, we shipped to a record 83,500 Invisalign doctors worldwide, of which approximately 7,200 were first-time customers.

    就隱形矯正器(Clear Aligners)而言,第二季營收為 8.41 億美元,較前一季成長 11.6%,較去年同期成長 181.9%,反映 Invisalign 在多數地區的出貨量成長。第二季我們出貨創紀錄的 665,600 例 Invisalign 病例,較前一季增加 11.7%,較去年同期增加 200%。此外,我們向全球創紀錄的 83,500 位 Invisalign 醫師出貨,其中約 7,200 位為首次購買的客戶。

  • Q2 Clear Aligner revenues reflect strong growth across the Invisalign portfolio for both comprehensive and noncomprehensive products. Q2 comprehensive volume increased 11.4% sequentially and 181.9% year-over-year. In Q2, non-comprehensive volume increased 12.3% sequentially, driven by strength in Invisalign Moderate and Invisalign Go and up 251.7% year-over-year. Q2 adult patients increased 12.6% sequentially and 220.4% year-over-year. In Q2, teens or younger patients increased 9.5% sequentially and 156.3% year-over-year. Clear Aligner revenues were unfavorably impacted by foreign exchange of approximately $3.4 million or approximately 0.5 points sequentially. On a year-over-year basis, Clear Aligner revenues were favorably impacted by foreign exchange of approximately $36.7 million or approximately 12.3 points.

    第二季隱形矯正器營收反映 Invisalign 產品組合在全療程與非全療程產品上的強勁成長。第二季全療程(comprehensive)出貨量較前一季增加 11.4%,較去年同期增加 181.9%。第二季非全療程(non-comprehensive)出貨量較前一季增加 12.3%,主要由 Invisalign Moderate 與 Invisalign Go 的強勁表現帶動,且較去年同期增加 251.7%。第二季成人患者數較前一季增加 12.6%,較去年同期增加 220.4%。第二季青少年或更年輕患者數較前一季增加 9.5%,較去年同期增加 156.3%。隱形矯正器營收受到外匯不利影響約 340 萬美元,或約 0.5 個百分點(相較前一季)。以年對年而言,隱形矯正器營收受到外匯有利影響約 3,670 萬美元,或約 12.3 個百分點。

  • For Q2, Invisalign comprehensive ASPs decreased sequentially and year-over-year. On a sequential basis, Invisalign comprehensive ASPs reflect higher discounts, credits and foreign exchange, partially offset by regional mix. On a year-over-year basis, comprehensive ASPs reflect the increase in net revenue deferrals for new Invisalign cases versus additional aligner shipments, partially offset by foreign exchange. Recall Q2 2020 ASPs increased as a result of more additional shipments -- of aligner shipments as doctors were focused on maintaining treatment progress for existing Invisalign patients. This trend reversed itself after practices reopened in Q3 and demand for new cases ramped up significantly.

    第二季 Invisalign 全療程的平均銷售單價(ASP)較前一季及較去年同期皆下降。就季對季而言,Invisalign 全療程 ASP 反映較高的折扣、折讓(credits)與外匯影響,部分被區域組合所抵銷。就年對年而言,全療程 ASP 反映新 Invisalign 病例相較於追加矯正器出貨的淨營收遞延增加,部分被外匯所抵銷。回顧 2020 年第二季,ASP 因追加出貨較多而上升——當時醫師著重於維持既有 Invisalign 患者的治療進度。在診所於第三季重新開放後,此趨勢反轉,且新病例需求顯著攀升。

  • Q2 Invisalign non-comprehensive ASPs increased sequentially and were flat year-over-year. On a sequential basis, Invisalign non-comprehensive ASPs reflect lower discounts, partially offset by foreign exchange. On a year-over-year basis, Invisalign non-comprehensive ASPs were favorably impacted by foreign exchange, offset by higher mix of new Invisalign cases versus additional aligner shipments.

    第二季 Invisalign 非全療程 ASP 較前一季上升,年對年持平。就季對季而言,Invisalign 非全療程 ASP 反映較低的折扣,部分被外匯影響所抵銷。就年對年而言,Invisalign 非全療程 ASP 受到外匯有利影響,但被新 Invisalign 病例占比提高(相較於追加矯正器出貨)所抵銷。

  • Clear Aligner deferred revenues on the balance sheet increased $101 million sequentially and $337 million year-over-year and will be recognized as the additional aligners are shipped.

    資產負債表上的隱形矯正器遞延收入較前一季增加 1.01 億美元,較去年同期增加 3.37 億美元,並將在追加矯正器出貨時認列。

  • Our System and Services revenues for the second quarter were a record $169.8 million, up 20% sequentially and up 214.7% year-over-year. The increase sequentially and year-over-year can be attributed to increased scanner shipments, higher ASP and increased services revenue for our larger installed base. Our Systems and Services revenue -- deferred revenue on the balance sheet was up 22% sequentially and up 135% year-over-year, primarily due to the increase in scanner sales and the deferral of service revenues, which will be recognized ratably over the service period.

    第二季我們的系統與服務(System and Services)營收創紀錄達 1.698 億美元,較前一季成長 20%,較去年同期成長 214.7%。季對季與年對年的成長可歸因於掃描儀出貨增加、ASP 提高,以及因安裝基礎擴大而帶來的服務營收增加。我們的系統與服務營收——資產負債表上的遞延收入——較前一季增加 22%,較去年同期增加 135%,主要因掃描儀銷售增加及服務營收遞延所致;該等遞延服務營收將於服務期間按比例認列。

  • Moving on to gross margin. Second quarter gross margin was 75%, down 0.6 points sequentially and up 11.4 points year-over-year. On a non-GAAP basis, excluding stock-based compensation and amortization of intangibles related to our exocad acquisition, overall gross margin was 75.4% for the second quarter, down 0.7 points sequentially and up 11 points year-over-year. Overall, gross margin was favorably impacted by approximately 1.1 points on a year-over-year basis due to foreign exchange and relatively unchanged sequentially.

    接著談毛利率。第二季毛利率為 75%,較前一季下降 0.6 個百分點,較去年同期上升 11.4 個百分點。以非 GAAP 基礎計算,排除以股份為基礎之薪酬及與收購 exocad 相關的無形資產攤銷後,第二季整體毛利率為 75.4%,較前一季下降 0.7 個百分點,較去年同期上升 11 個百分點。整體而言,毛利率在年對年比較下因外匯而約有 1.1 個百分點的有利影響,而季對季則大致不變。

  • Clear Aligner gross margin for the second quarter was 76.9%, down 0.7 points sequentially due to higher freight costs and slightly lower ASPs. Clear Aligner gross margin was up 12.4 points year-over-year due to increased manufacturing efficiencies from higher production volumes, partially offset by lower ASPs. Systems and Services gross margin for the second quarter was a record 65.9%, up 0.5 points sequentially, primarily due to higher ASPs, partially offset by manufacturing variances and higher freight costs. Systems and Services gross margin was up 6.6 points year-over-year due to higher ASPs and services revenues in addition to improved manufacturing efficiencies from higher production volumes, partially offset by higher freight costs.

    第二季隱形矯正器毛利率為 76.9%,較前一季下降 0.7 個百分點,主因運費成本較高及 ASP 略降。隱形矯正器毛利率較去年同期上升 12.4 個百分點,主因產量提高帶來製造效率提升,部分被 ASP 較低所抵銷。第二季系統與服務毛利率創紀錄達 65.9%,較前一季上升 0.5 個百分點,主要因 ASP 較高,部分被製造差異與較高運費成本所抵銷。系統與服務毛利率較去年同期上升 6.6 個百分點,主因 ASP 與服務營收提高,以及產量提升帶來製造效率改善,部分被較高運費成本所抵銷。

  • Q2 operating expenses were $489.6 million, up sequentially 8.4% and up 64.7% year-over-year. The sequential increase in operating expenses is due to increased consumer marketing spend, increased compensation related to additional head count and higher commissions and other general and administrative costs. Year-over-year, operating expenses increased by $192.3 million, reflecting our continued investment in marketing and sales and R&D activities and investments commensurate with business growth. On a non-GAAP basis, which includes (sic) [excludes] stock-based compensation and amortization of intangibles related to our exocad acquisition, operating expenses were $461.2 million, up sequentially 8.6% and up 73.6% year-over-year due to the reasons described above.

    第二季營業費用為 4.896 億美元,較前一季增加 8.4%,較去年同期增加 64.7%。營業費用的季對季增加,係因消費者行銷支出增加、因新增人力而提高的薪酬支出,以及較高的佣金與其他一般及行政費用。年對年而言,營業費用增加 1.923 億美元,反映我們持續投入行銷與銷售、研發活動,以及與業務成長相匹配的投資。以非 GAAP 基礎計算(此處 includes(原文如此)[應為 excludes]:排除以股份為基礎之薪酬及與收購 exocad 相關的無形資產攤銷),營業費用為 4.612 億美元,較前一季增加 8.6%,較去年同期增加 73.6%,原因如上所述。

  • Our second quarter operating income of $268.9 million resulted in an operating margin of 26.6%, up 1.4 points versus prior quarter and up 47.3 points year-over-year. The sequential increase in operating margin was attributed primarily to operational leverage. The year-over-year increase in operating margin was primarily attributed to higher gross margin and operating leverage as well as a favorable impact from foreign exchange by approximately 1.8 points. On a non-GAAP basis, which excludes stock-based compensation and amortization of intangibles, operating margin for the second quarter was 29.8%, up 1.2 points sequentially and up 40.8 points year-over-year.

    第二季營業利益為 2.689 億美元,營業利益率為 26.6%,較前一季上升 1.4 個百分點,較去年同期上升 47.3 個百分點。營業利益率的季對季提升主要歸因於營運槓桿。營業利益率的年對年提升主要歸因於較高的毛利率與營運槓桿,並且外匯帶來約 1.8 個百分點的有利影響。以非 GAAP 基礎計算,排除以股份為基礎之薪酬及無形資產攤銷後,第二季營業利益率為 29.8%,較前一季上升 1.2 個百分點,較去年同期上升 40.8 個百分點。

  • Interest and other income and expense net for the second quarter was a loss of $0.1 million, down sequentially by $36.3 million primarily due to the SDC arbitration award gain recorded in the first quarter.

    第二季利息及其他收入與費用淨額為虧損0.1百萬美元,較前一季下降36.3百萬美元,主要因第一季認列了SDC仲裁裁決收益。

  • With regards to the second quarter tax provision, our GAAP tax rate was 25.7%, which was higher than the prior quarter rate of 23.4%, primarily due to lower excess tax benefits from stock-based compensation. Our GAAP tax rate was lower than the same quarter last year, which was 44.8%, primarily due to foreign income tax at lower rates. The second quarter tax rate on a non-GAAP basis was 19.5% compared to 20.2% in the prior quarter and 27.8% in the prior year. The second quarter non-GAAP tax rate was lower than the prior quarter and the second quarter of the prior year rates due to foreign income tax and lower rates.

    關於第二季所得稅費用,我們的GAAP有效稅率為25.7%,高於前一季的23.4%,主要因股票基礎薪酬帶來的超額稅務利益較低。我們的GAAP有效稅率低於去年同期的44.8%,主要因海外所得適用較低稅率。以非GAAP基礎計算,第二季稅率為19.5%,相較前一季的20.2%及前一年度的27.8%。第二季非GAAP稅率低於前一季及前一年度第二季,係因海外所得稅及較低稅率所致。

  • Second quarter net income per diluted share was $2.51, flat sequentially and up $3.03 compared to the prior year. On a non-GAAP basis, net income per diluted share was $3.04 for the second quarter, up $0.55 sequentially and up $3.39 year-over-year.

    第二季稀釋後每股淨利為2.51美元,較前一季持平,較去年同期增加3.03美元。以非GAAP基礎計算,第二季稀釋後每股淨利為3.04美元,較前一季增加0.55美元,年增3.39美元。

  • Moving on to the balance sheet. As of June 30, 2020, cash and cash equivalents were $1.1 billion, flat sequentially. Of our $1.1 billion of cash and cash equivalents, $551 million was held in the U.S., and $535.3 million was held by our international entities. Q2 accounts receivable balance was $808.1 million, up approximately 12.4% sequentially. Our overall days sales outstanding was 72 days, flat sequentially and down approximately 49.1 days as compared to Q2 last year. Cash flow from operations for the second quarter was $317.5 million. Capital expenditures for the second quarter were $124.2 million, primarily related to our continued investment in increasing aligner capacity and facilities. Free cash flow, defined as cash flow from operations less capital expenditures, amounted to $193.3 million. We also have $300 million available under our revolving line of credit. Under our $1 billion repurchase program announced in May 2021, we have $900 million remaining available for repurchase of our common stock.

    接著談資產負債表。截至2020年6月30日,現金及約當現金為11億美元,較前一季持平。在我們11億美元的現金及約當現金中,5.51億美元存放於美國,5.353億美元由海外子公司持有。第二季應收帳款餘額為8.081億美元,較前一季約增加12.4%。整體應收帳款週轉天數(DSO)為72天,較前一季持平,較去年第二季約減少49.1天。第二季營運活動現金流量為3.175億美元。第二季資本支出為1.242億美元,主要與我們持續投資以提升隱形矯正器產能及設施相關。自由現金流量(定義為營運活動現金流量減資本支出)為1.933億美元。我們在循環信用額度下另有3億美元可用額度。在我們於2021年5月宣布的10億美元庫藏股回購計畫下,尚有9億美元可用於回購普通股。

  • Now let me turn to our outlook and the factors that inform our view for the remainder of the year. Overall, we are very pleased with our second quarter results and our continued strong performance across regions, customer channels and products. While there continues to be uncertainty around the pandemic and increasing restrictions related to COVID-19 in certain geographies, we are continuing to invest in our strategic growth initiatives, including sales, marketing, innovation and manufacturing capacity, to drive demand and conversion globally and are confident in our competitive position and ability to execute. At the same time, we are also anticipating more pronounced summer seasonality across all regions than we have experienced in recent years as doctors, their staff and patients take long overdue vacations.

    接下來我將談談我們的展望,以及支撐我們對今年剩餘期間看法的因素。整體而言,我們對第二季成果以及在各地區、客戶通路與產品上的持續強勁表現感到非常滿意。儘管疫情仍具不確定性,且部分地區因COVID-19而加強限制措施,我們仍持續投資於策略性成長計畫,包括銷售、行銷、創新與製造產能,以在全球推動需求與轉換;我們對自身競爭地位與執行能力充滿信心。同時,我們也預期今年夏季在所有地區的季節性將比近年更為明顯,因醫師、其員工與病患將進行久違的休假。

  • Notwithstanding seasonality, given our strong performance and continued confidence in the huge market opportunity, our industry leadership and our ability to execute, we are increasing our 2021 revenue guidance provided in April on the Q1 '21 earnings call to a range of $3.85 billion to $3.95 billion. Additionally, we now expect our second half year-over-year revenue growth rate to be above the midpoint of our long-term operating model target of 20% to 30%. On a GAAP basis, we now anticipate our 2021 operating margin to be better than our prior guidance in the range of 24% to 25%. On a non-GAAP basis, we expect the 2021 operating margin to be approximately 3 points higher than our GAAP operating margin after excluding stock-based compensation and intangible amortization.

    撇開季節性因素不談,鑑於我們的強勁表現、對龐大市場機會的持續信心、產業領導地位以及執行能力,我們將在4月於2021年第一季財報電話會議中提供的2021年營收指引上調至38.5億至39.5億美元。此外,我們目前預期下半年年對年營收成長率將高於我們長期營運模型目標20%至30%的中位數。以GAAP基礎計算,我們目前預期2021年營業利益率將優於先前指引,落在24%至25%區間。以非GAAP基礎計算,在排除股票基礎薪酬與無形資產攤銷後,我們預期2021年營業利益率將較GAAP營業利益率高約3個百分點。

  • In addition, during Q3 '21, we expect to repurchase up to $75 million of our common stock through either a combination of open market repurchases or an accelerated stock repurchase agreement. For 2021, we expect our investments in capital expenditures to be approximately $500 million. Capital expenditures primarily relate to building construction and improvements as well as additional manufacturing capacity to support our international expansion. This includes our planned investment in a new manufacturing facility in Poland, our first one in the EMEA region.

    另外,在2021年第三季期間,我們預期將透過公開市場回購與/或加速股票回購協議的組合,回購最多7,500萬美元的普通股。對於2021年,我們預期資本支出投資約為5億美元。資本支出主要用於建築工程與改善,以及增加製造產能以支援我們的國際擴張。其中包括我們計畫投資於波蘭的新製造工廠,這將是我們在EMEA地區的第一座工廠。

  • With that, I'll turn it back over to Joe for final comments. Joe?

    接下來,我把時間交還給Joe做最後的評論。Joe?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Thanks, John. Q2 was a terrific quarter and we're very pleased with the improvements we've seen in recovery in doctor practices. We truly value their increasing adoption of digital treatment approaches. Their confidence in the unique Align Digital Platform that spans from iTero to the world's most sophisticated treatment planning, the world's largest 3D printing business on the globe to a patient app worth -- with over -- with 1 million consumers along with the world's most recognized orthodontic brand has driven strong performance across the business.

    謝謝,John。第二季表現非常出色,我們對於看到牙醫診所復甦的改善感到非常滿意。我們非常重視他們對數位治療方式日益提高的採用。他們對獨特的Align數位平台的信心——涵蓋從iTero到全球最先進的治療規劃、全球最大的3D列印業務,以及擁有超過100萬名消費者的病患App,再加上全球最具辨識度的齒顎矯正品牌——推動了公司各項業務的強勁表現。

  • Our performance over the last year confirms the incredible size of our target market and demonstrates that our strategy and investments in recent years have helped further solidify our competitive position. We have numerous growth drivers in a vastly underpenetrated market. And while we continue to see some lasting impact and continued uncertainty due to COVID, we remain confident in both the enormous opportunity we have to lead the evolution of digital orthodontics and comprehensive dentistry with our doctor customers and in our ability to execute our strategy to increase adoption of Invisalign treatment globally.

    我們過去一年的表現證實了目標市場規模之龐大,也顯示我們近年的策略與投資已進一步鞏固競爭地位。在一個滲透率仍然很低的市場中,我們擁有眾多成長動能。儘管我們仍看到COVID帶來的一些持續影響與不確定性,我們仍對兩件事充滿信心:一是我們有巨大的機會與醫師客戶一起引領數位齒顎矯正與全方位牙科的演進;二是我們有能力執行策略,在全球提升Invisalign療程的採用。

  • We're also confident in and excited about the benefits of digital treatment that more and more doctors are experiencing by transforming their practices with Invisalign digital orthodontics and iTero scanners for chairside treatment, planning and visualization. In fact, Invisalign treatment requires, on an average, 30% fewer doctor visits than fixed appliances, creating efficiency gains for the doctors and a better patient experience. And 85% of orthodontists surveyed agreed that adopting the Align Digital Platform have made a huge difference in their practices. It provides ways to improve their efficiency and productivity.

    我們也對越來越多醫師透過Invisalign數位齒顎矯正與iTero口內掃描儀,在椅旁進行治療、規劃與可視化,進而改造其診所所帶來的數位治療效益感到有信心並且興奮。事實上,平均而言,Invisalign療程所需的回診次數比固定式矯正器少30%,可為醫師帶來效率提升,並提供更佳的病患體驗。受訪的齒顎矯正醫師中有85%同意,採用Align數位平台已對其診所帶來巨大改變。該平台提供改善效率與生產力的方法。

  • I look forward to updating you at the GP Summit and Investor Day in October in Las Vegas and sharing more examples of how Align is helping doctors transform their practices and their approach to treatment.

    我期待在10月於拉斯維加斯舉行的GP高峰會與投資人日向各位更新,並分享更多Align如何協助醫師改造其診所與治療方式的案例。

  • Now I'll turn the call over to the operator for questions. Operator?

    現在我把電話交給接線員進行問答。接線員?

  • Operator

    Operator

  • (Operator Instructions) Our first question comes from Nathan Rich with Goldman Sachs.

    (接線員指示) 我們的第一個問題來自高盛(Goldman Sachs)的Nathan Rich。

  • Nathan Allen Rich - Research Analyst

    Nathan Allen Rich - Research Analyst

  • Joe, I wanted to start with the increased guidance and expectations around the back half of the year being at the high end of the long-term range. I guess several of the factors that you highlighted on the call, the growth in new customers, the strong iTero placements, those have all historically been good leading indicators of growth in Invisalign. It also sounds like you're seeing better uptake from the DSO channels. That's obviously an opportunity that you guys have been going after for a long time. So I guess at this point, does that change how you're thinking about what the right target is for top line growth kind of next year within the long-term range that you have?

    Joe,我想先從上調指引以及對下半年營收成長預期將位於長期區間高端的看法談起。我想你在電話會議中提到的幾個因素——新客戶成長、強勁的iTero裝機量——歷來都是Invisalign成長的良好領先指標。聽起來你們也看到來自DSO通路更好的採用動能。那顯然是你們長期以來一直在努力開拓的機會。所以我想問的是,在目前這個時間點,這是否改變你們對明年在既有長期區間內,營收(top line)成長適當目標的思考?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Nathan, look, I think you cited really well what we're seeing right now, what we're experiencing overall. And we are calling strong growth for the second half of this year. But look, our revenue guidance is for the long term -- for the business is 20% to 30%, and we continue to work within those boundaries. So we're not prepared to change that at the moment. John, any thoughts on your...

    Nathan,你看,我認為你把我們目前所看到、整體所經歷的情況引用得非常到位。而我們預期今年下半年將有強勁成長。但你看,我們的營收指引是以長期為主——就業務而言是20%到30%,我們也持續在這些界限內運作。所以我們目前還沒有準備要改變它。John,你有什麼想法關於你的……

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • No. That's exactly -- we feel good about the -- what we're seeing in the marketplace, and our guide reflects that.

    沒有。完全是——我們對——我們在市場上看到的情況感到很有信心,而我們的指引也反映了這一點。

  • Nathan Allen Rich - Research Analyst

    Nathan Allen Rich - Research Analyst

  • Appreciate that. And then, John, maybe a follow-up for you. Could you maybe go into a little bit more detail around your comments on the more pronounced summer seasonality? Just how that impacts your expectations for the sequential growth we're likely to see in 3Q and 4Q of this year maybe versus what you would expect in a normal year.

    感謝說明。然後,John,或許我再追問一下。你能否就你提到「夏季季節性更為明顯」的評論再多提供一些細節?這會如何影響你對今年第3季與第4季可能出現的環比成長的預期,相較於你在正常年份會期待的情況。

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Well, as we know, I mean there's summer period where people take vacations, holidays and so on in EMEA and other places, and we expect -- and I think what we see in our own lives is you take longer weekends or maybe more pronounced vacations, people doing things in advance of shutdowns or lockdowns that might happen. And I think we're just being reflective of that but really looking at all the variables that we normally see. And talking to the -- what we expect for the second half, which is to the upper point or upper side of our midpoint on a year-over-year basis.

    嗯,眾所周知,夏季期間人們會在EMEA及其他地區度假、放假等等,我們預期——而且我想從我們自己的生活也能看到——你會安排較長的週末,或是更明顯的假期;人們也會在可能發生的停工或封鎖之前先把事情提前處理。我想我們只是把這些因素反映在預期中,同時也會檢視我們通常會看到的所有變數。並且談到——我們對下半年的預期,是以年對年來看,落在我們中點的較高端或偏上側。

  • Operator

    Operator

  • Our next question comes from Jon Block with Stifel.

    下一個問題來自Stifel的Jon Block。

  • Jonathan David Block - MD & Senior Equity Research Analyst

    Jonathan David Block - MD & Senior Equity Research Analyst

  • I think Joe, I'll start with you with the first one. The -- I think it was 5.3 North American GP utilization number -- was huge. And I think we all waited for a while to get that -- to get to 4. Now it's worth a 5. Just talk to us on what that is. I mean I'm assuming it's what -- it's more scanners. Is it also just increased utilization with even those that have had the scanner for some time? Would love some color. And maybe just more importantly, is that 5 handle on the North American GP utilization, do you view that as sustainable going forward? And then I've got a follow-up.

    我想Joe,我先從第一個問題問你。——我想那個北美GP利用率5.3的數字——非常驚人。我想我們都等了好一陣子才看到它——先到4,現在值得一個5。請跟我們談談這代表什麼。我的意思是,我假設這是——更多掃描儀。那是否也包括即使是已經擁有掃描儀一段時間的診所,其使用率也提高了?很希望你能多給一些背景。而且也許更重要的是,北美GP利用率達到5這個水準,你認為未來能否持續?然後我還有一個追問。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Jon, I consider everything we do has more than a single variable to it, and that's the platform that we work with, which you know as well as anybody. But I'd say, yes, scanners serve that very well. Our increased advertising helps to drive that, too. It brings more patients to the GPs. And thirdly, new products like what we're working, iGO and different derivatives of that product line that are very efficient for GPs to use, and it gives them a huge amount of confidence in our product line when they use it, Jon. So it's a combination of our brand. It's a combination of a digital platform with iTero. It's a combination of product piece.

    Jon,我認為我們做的每件事都不只是一個變數,而是我們所運作的平台——你跟任何人一樣清楚。但我會說,是的,掃描儀在這方面確實很有幫助。我們增加的廣告投放也有助於推動這一點。它把更多病患帶到GP那裡。第三,新產品,例如我們正在推進的iGO以及該產品線的不同衍生版本,對GP而言使用效率很高;當他們使用時,會對我們的產品線建立非常大的信心,Jon。所以這是我們品牌的組合。這是以iTero為核心的數位平台的組合。這也是產品本身的組合。

  • And then we don't talk about it a lot, but we split our sales force years ago. And we have a specific focused sales force on GPs. And being a GP speak a different language, Jon. It's different than orthodontists altogether. And that team has been incredibly effective in being able to work with doctors, how they can integrate Invisalign into their workflow and, from a restorative standpoint, how you use this proactively. So we're -- I'm confident. That's a great market for us. We know that 500 million patients we talk about globally sits broadly in that segment and -- but you need a different kind of a product approach, a different sales approach and a strong platform geared to those guys to keep that going. And we feel good about that.

    另外我們不常談到,但我們多年前就把銷售團隊做了分拆。我們有一支專門聚焦GP的銷售團隊。而且GP講的是不同的語言,Jon。這跟矯正醫師完全不同。那個團隊在與醫師合作方面非常有效,能協助他們把Invisalign整合進工作流程,並且從修復(restorative)的角度,如何更主動地使用它。所以我們——我很有信心。那對我們來說是一個很棒的市場。我們知道我們常提到的全球5億名病患,廣泛地就落在那個區隔中——但你需要不同的產品策略、不同的銷售策略,以及一個針對那些客群打造的強大平台,才能讓這件事持續推進。而我們對此感覺良好。

  • Jonathan David Block - MD & Senior Equity Research Analyst

    Jonathan David Block - MD & Senior Equity Research Analyst

  • Yes. And actually, you brought up an interesting point. I think that the sales force, I believe, bifurcated international more recently in North America. So I guess we're starting to see that come through.

    是的。而且其實你提到了一個有趣的點。我認為銷售團隊在國際市場的分拆,是在北美之後、相對更近期才做的。所以我想我們開始看到這個效果反映出來了。

  • Second question, John, just let me try to be as detailed as possible. So you've got solid 2Q '21 sales upside that you just reported. Then you raised the back part of the year from roughly 25% year-over-year revenue midpoint growth to closer to 27%. Yet you call out some more pronounced summer seasonality. And those seem at odds with one another. So can you just reconcile those 2 data points? In other words, you're alluding to more seasonality. Yet you just took up the forecast in the back part of the year even in the face of that. So any color would be great.

    第二個問題,John,讓我盡量把問題講得具體一些。你剛公布的2021年第二季銷售表現優於預期,幅度不小。接著你把下半年從原本大約年對年營收中點成長25%上調到更接近27%。但你又提到夏季季節性更為明顯。這兩者看起來彼此矛盾。你能否把這兩個數據點做個調和說明?換句話說,你在暗示季節性更強。但即便如此,你仍上調了下半年的預測。如果能多給一些背景就太好了。

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • I think it really reflects just the timing between quarters and not kind of as you said, looking at the second half in a way, not knowing how vacations and holidays and lockdowns' potential might play out, but looking at it in totality and kind of looking at it from a second half standpoint.

    我認為這其實反映的是季度之間的時點差異;並不是像你說的那樣,以某種方式去看下半年、卻不知道假期、節日以及封鎖可能如何發展,而是把它作為整體來看,並且從下半年的角度來評估。

  • Operator

    Operator

  • Our next question comes from Jason Bednar with Piper Sandler.

    下一個問題來自Piper Sandler的Jason Bednar。

  • Jason M. Bednar - VP & Senior Research Analyst

    Jason M. Bednar - VP & Senior Research Analyst

  • Joe, I wanted to follow up on Nathan's question there, going back to the first one. Maybe if you can unpack a bit further what you're seeing here as we look ahead in the next couple of quarters, especially now that we've lapped the easiest of your comps. Your guide here would suggest the momentum is strong across the business. But the key question I keep getting from investors is really how that adult consumer in the second half of the year and then into '22, how they're going to respond. So the question, I guess, for you is just how you're seeing the adult consumer respond in your various geographies as economies have opened back up and as we start staring down some tougher comps in the adult side? And I've got a follow-up.

    Joe,我想接續Nathan剛才的問題,回到第一個問題再追問一下。也許你可以再進一步拆解一下,當我們展望接下來幾個季度時,你們看到的是什麼,特別是現在你們已經度過了最容易的比較基期。你們的指引顯示整體業務動能很強。但我從投資人那裡一直被問到的關鍵問題是:今年下半年以及進入2022年,成人消費者會如何反應。所以我想問的是,隨著各地經濟重新開放、且我們開始面對成人端更具挑戰的比較基期,你在不同地區看到成人消費者的反應如何?我還有一個追問。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Well, I think Jason, in what we see with adults, and we see this really all over the globe, is we obviously had a big uptake from an adult standpoint. But you can see our teen numbers up pretty substantially, too, at the same time. So it's a good balance. The previous question that Jon asked, too, with GPs, it comes in -- broadly in adult segment, in that segment also. And my explanation in the sense of why we've been effective in that segment, we think we can continue to be -- helps to contribute to that.

    Jason,我認為我們在成人端看到的——而且這其實是全球各地都一樣——是我們確實在成人方面有很大的採用提升。但同時你也可以看到我們的青少年數字也相當大幅成長。所以這是一個很好的平衡。Jon剛才問到的GP那個問題,也涵蓋在——廣義上屬於成人區隔——那個區隔裡。而我對於我們為何能在那個區隔有效、並且我們認為可以持續有效的解釋,也有助於支撐這一點。

  • Now when we talk about third quarter and seasonality or John talking about whatever, a lot of that is around adult patients and vacations and different things, too, and it affects different parts of the organization, but -- and how we go to market. But in general, we just feel good about the direction of the business, the signal and words that we're getting from our doctors and what they're explaining they're seeing out there. And that's all incorporated into what we've been forecasting for you.

    現在當我們談到第三季與季節性,或John提到的那些情況時,其中很多也與成人病患、假期以及各種因素有關;它也會影響組織的不同部分,以及——我們的市場推進方式。但整體而言,我們對業務的走向感到樂觀,對我們從醫師那裡得到的訊號與回饋——以及他們所描述在市場上看到的情況——感到正面。而這些都已納入我們提供給你們的預測之中。

  • The one thing to never forget about, too, Jason is the size of this marketplace. We talk about 500 million patients, and I know you hear from a lot of other companies in different industries about oversized sims and whatever. This is true. If anything's sort of shown -- like I mentioned in my closing comments that this market is as big as we talked about being as what you've seen from this business over the last year and in the adult segment of that part, too, which is a big part of that 500 million patients that we talked about.

    還有一點千萬別忘了,Jason,就是這個市場的規模。我們談的是5億名患者;我知道你也會從其他產業的很多公司那裡聽到所謂「超大」的可服務市場(SAM)之類的說法。但這次是真的。如果說有什麼能證明——就像我在結語提到的——這個市場確實如我們所說的那麼大,從你過去一年在這項業務上看到的表現,以及其中成人細分市場的部分也是如此;而成人其實也是我們所說那5億名患者中的很大一部分。

  • Jason M. Bednar - VP & Senior Research Analyst

    Jason M. Bednar - VP & Senior Research Analyst

  • All right. That's helpful, Joe. And then just looking at least relative to our model in the quarter, it looks like most of the outperformance or disproportionate amount came from the Americas. I'm sure that's U.S., but also maybe Brazil, and you've made some pretty strong comments in the past on what Brazil could do for your business in a pretty short window of time. So just wondered if you could update us here on where you're at with expansion in Brazil. Maybe how much of that market in particular is contributing to sequential case growth.

    好。這很有幫助,Joe。另外,至少相對於我們本季模型來看,似乎大部分的超預期或較不成比例的貢獻來自美洲地區。我確定主要是美國,但也可能包含巴西;而你過去也對巴西在相當短的時間內能為你們業務帶來什麼,做過一些相當強烈的評論。所以想請你更新一下你們在巴西擴張的進度。以及特別是巴西市場目前對於連續季度病例量成長的貢獻大概有多少。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes, no statistics for it. Brazil continues to be strong. I think you know it's a big aesthetic market. It's one of the biggest aesthetics markets in the world. It parallels Iberia in a lot of ways as we -- how we have to go in there and move. We're primarily in the orthodontic segment there, not in the GP segment right now and how we have done it. And it's a different market that way because orthos play in a much more broader sense in that country than what we do here. But we have a very experienced team there. We funded it well. I feel good about our position from a product standpoint and iTero scanners. And it's a big market for us. And don't just think about Brazil, too. Latin America, in general, it's been a big expanding market for us. So Brazil leads because of the size of population and aesthetics we talked about. But overall, our Lat Am market is extremely strong, and we're well positioned there. John, any thoughts on that?

    是的,這部分沒有統計數字可提供。巴西仍然表現強勁。我想你也知道,那是一個很大的醫美市場。它是全球最大的醫美市場之一。在很多方面它和伊比利亞半島很相似,就像我們——我們必須如何進入並推進那個市場。我們目前主要在那裡的矯正(orthodontic)領域,而不是一般牙科(GP)領域,這是我們的做法。因此它在這方面是不同的市場,因為在那個國家,矯正醫師的業務覆蓋面比我們在這裡所看到的更廣。但我們在當地有一支非常有經驗的團隊。我們也給了充足的資金支持。從產品面以及 iTero 掃描儀來看,我對我們的定位很有信心。而且那對我們來說是一個大市場。另外也不要只看巴西。拉丁美洲整體而言,一直是我們快速擴張的市場。所以巴西因為人口規模以及我們談到的醫美需求而領先。但總體來說,我們的拉美市場非常強勁,我們在那裡的布局也很到位。John,你對這點有什麼補充嗎?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • You covered it.

    你都講到了。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • All right.

    好。

  • Operator

    Operator

  • Our next question comes from Erin Wright with Credit Suisse.

    下一個問題來自 Credit Suisse 的 Erin Wright。

  • Erin Wright

    Erin Wright

  • Okay. Great. Sticking with that international topic, can you speak to the growth in the quarter in Asia Pac and what you're seeing across that market? Are you still seeing some COVID-related lingering headwinds there? And can you speak to some of the competitive landscape dynamics as well and then also your efforts in terms of expanding the consumer advertising effort across that geography as well?

    好的。很好。延續國際市場的話題,你能談談本季亞太地區(Asia Pac)的成長,以及你在該市場看到的情況嗎?那邊是否仍有一些與 COVID 相關、尚未消退的逆風?也請你談談競爭格局的一些動態,以及你們在該地區擴大消費者廣告投放方面的努力。

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Erin, this is John. I can address the start of that. Look, APAC is an important region for us, a huge market opportunity. We've invested, as we've talked about, with manufacturing and treatment plan in other places. We recently have added some advertising -- additional advertising in APAC, and we see great results where there's a lot of interest, a lot of awareness that it drives. People come to our website and look for doctors and so on. And we think that translates very well. We're very happy with the quarter for Q2. You have -- you do have pockets of areas where there's COVID -- more of a COVID impact, Southeast Asia, parts of China, other areas that we're always mindful of. But when we look at the investments we're making, the return that we're getting from those investments, we feel really good about APAC.

    Erin,我是 John。我先回應前半段。你看,亞太對我們而言是重要區域,也是巨大的市場機會。如同我們先前談過的,我們已在製造與治療方案規劃等方面於其他地點進行投資。我們最近在亞太增加了一些廣告——額外的廣告投放——而且在有大量興趣與高度認知被帶動的地方,我們看到很好的成效。人們會到我們的網站,尋找醫師等等。我們認為這樣的轉化效果非常好。我們對第二季(Q2)的表現非常滿意。當然也有一些區域仍受 COVID 影響較大,例如東南亞、中國部分地區,以及其他我們一直密切留意的地方。但就我們所做的投資,以及這些投資帶來的回報來看,我們對亞太感覺非常好。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes.

    是的。

  • Erin Wright

    Erin Wright

  • Okay. And then how should we be thinking about the quarterly progression of the gross margin from here and the run rate going forward? Is this -- is there anything to call out in terms of mix or ASPs or some of those seasonal dynamics you were talking about that we should be thinking about as we think about the third and the fourth quarter gross margin trend?

    好的。那接下來我們該如何看待毛利率從現在起的季度走勢,以及未來的常態水準(run rate)?在你先前提到的季節性因素下,是否有任何需要特別指出的,例如產品組合(mix)、平均售價(ASPs)或其他季節性動態,讓我們在思考第三、第四季毛利率趨勢時納入考量?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Nothing of major note, Erin. I mean we've seen that as we drive utilization, have more coming through our factories, very productive for us, we're very mindful of the trade-offs that affect our margin, and you're seeing that come through. So as we look at some of the investments that we're making and how we're going to market, products that we have, how we view things, there's nothing that should be too different than what we've seen from a gross margin standpoint.

    Erin,沒有什麼特別重大的事項。我的意思是,隨著我們提升產能利用率、讓更多量能通過工廠,對我們而言生產效率很高;我們也非常留意會影響毛利率的各種取捨,而你也看到這些反映在結果上。因此,從我們正在進行的投資、我們的市場推進方式、我們的產品,以及我們看待各項事情的角度來看,毛利率面不太會和我們目前看到的情況有太大差異。

  • Operator

    Operator

  • Our next question comes from Jeff Johnson with Robert W. Baird & Co.

    下一個問題來自 Robert W. Baird & Co. 的 Jeff Johnson。

  • Jeffrey D. Johnson - Senior Research Analyst

    Jeffrey D. Johnson - Senior Research Analyst

  • A couple of questions here, I guess. One, on the seasonality -- and again, I hate to keep harping on that. But typically, by this point, late July, you guys now know July numbers. You probably know pretty much what's lined up for August given cases that are in treatment planning phase right now. So are the seasonality comments driven by something you're seeing so far in the numbers? Is it something that you're just expecting could come in late in the quarter? Is it focused on the adult side? Just kind of any more color there would be helpful as well.

    我這裡有幾個問題。第一個是關於季節性——我也不想一直糾結這點。但通常到現在這個時間點,7月下旬,你們應該已經知道7月的數字。考量目前正處於治療方案規劃階段的病例,你們大概也知道8月會排進來多少。所以你們提到季節性的評論,是基於你們目前在數字上已經看到的情況嗎?還是你們只是預期可能會在季度後段才出現?這是否主要集中在成人端?如果能再多給一些細節會很有幫助。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Jeff, it's just -- it's based on our experience with the season. I think you know. You've been following our business long enough. Third quarter is a real transition quarter, from a vacation standpoint, teens coming in here, European vacations, which are really big. And our comments is just reflecting what we're hearing from our customer base, our doctor bases not just in the United States but all over the world, and we're just trying to share that with you. But at the same time, the guidance that we've taken up, you have to remember we're at the upper end of our growth modeling for the second half. And when you think about it, we had 2 real strong quarters last year, Jeff, third and fourth quarter. So it shows a lot of confidence in what we see and what we feel.

    Jeff,這只是——基於我們對季節性的經驗。我想你也知道。你追蹤我們的業務已經夠久了。第三季確實是一個轉換季,從度假角度來看,青少年回診、歐洲度假季都很明顯,而歐洲的假期影響特別大。我們的評論只是反映我們從客戶端、醫師端聽到的情況,不僅在美國,而是在全球各地;我們只是想把這些分享給你。但同時,你也要記得我們上調了指引,這代表在下半年我們的成長模型已經處在較高端。而且你想想看,去年第三、第四季其實都有兩個非常強勁的季度,Jeff。所以這也顯示我們對所看到、所感受到的情況很有信心。

  • Jeffrey D. Johnson - Senior Research Analyst

    Jeffrey D. Johnson - Senior Research Analyst

  • Yes. Understood. And then on ASPs, John, maybe for you, it sounds like some of the rebating or some of the promotional activity, I guess I should say, maybe has stepped down just a little bit. Obviously, you're running some bigger trade-in programs in that late last year and the early part of this year. Is that an opportunity then for ASPs to float a little bit higher into the back half of next year? Or does -- do other promotions pop up and just think about ASPs kind of straight-lining from here?

    是的。了解。另外關於平均售價(ASPs),John,可能想請你回答:聽起來一些回饋(rebating)或我應該說促銷活動,似乎稍微減少了一點。很明顯你們在去年下半年到今年上半年初,推出了較大型的以舊換新方案。那這是否代表 ASP 有機會在明年下半年略為走高?還是說——會有其他促銷接續出現,讓 ASP 大致從這裡開始走平?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes. I would say the latter. I mean, look, there's always promotions that we're running to drive that right utilization and you try to find that right mix. And what we talk about and I think everybody gets is it has to translate to gross margin, and we feel good about the gross margin that is ultimately driving -- and our op margin that it brings to our bottom line. So there'll be some trade-offs, but I don't expect too much of a change in ASP. And the way we've looked at it -- and just because some grow faster than others, you look at it from a comprehensive standpoint versus a non-comprehensive standpoint to be relatively stable.

    是的。我會說是後者。我的意思是,你看,我們一直都有在跑一些促銷活動,以推動達到合適的使用率,你也會試著找到那個正確的組合。而我們所談的、我想大家都理解的是,這必須能轉化為毛利率;我們對最終所帶動的毛利率——以及它為我們帶來、反映在最終盈餘的營業利益率——感到滿意。所以會有一些取捨,但我不預期ASP會有太大的變化。而我們看待它的方式——也不只是因為有些成長比其他更快——是從全面性的角度而非非全面性的角度來看,整體會相對穩定。

  • Operator

    Operator

  • Our next question comes from John Kreger with William Blair.

    下一個問題來自 William Blair 的 John Kreger。

  • John Charles Kreger - Partner & Co-Group Head of Healthcare Technology and Services

    John Charles Kreger - Partner & Co-Group Head of Healthcare Technology and Services

  • Maybe just one more follow-up. I would assume the seasonality comment is mainly sort of one about adults, but curious if you've got any thoughts on how the teen season might differ this year. Is it shaping up to be sort of a normal year as we assume schools are open again or maybe more spread evenly across the second half?

    也許再追問一個。我猜季節性的評論主要是針對成人,但我想知道你們對今年青少年旺季可能會有何不同的看法。在我們假設學校又重新開放的情況下,今年看起來會是正常的一年,還是可能更平均地分散在下半年?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • I think you look at it, John, just from the standpoint that there are unknowns around COVID and vacations and other things. COVID is one of them. Some places -- we hear some of the countries and regions, schools going to open up earlier. Some are saying that it's later. So we're just trying to be mindful that there's going to be changes that happen to this and try to give as much information about that as possible.

    John,我認為你可以從這個角度來看:圍繞COVID、假期和其他事情仍有一些未知數。COVID就是其中之一。有些地方——我們聽到某些國家和地區——學校會更早開學。也有些說會更晚。所以我們只是試著留意,這裡面會發生變化,並盡可能提供更多相關資訊。

  • John Charles Kreger - Partner & Co-Group Head of Healthcare Technology and Services

    John Charles Kreger - Partner & Co-Group Head of Healthcare Technology and Services

  • Great. And then maybe one follow-up on ASP. It seemed like the year-over-year trend was different in comprehensive versus non-comprehensive. Could you just explain that again? Why would that comprehensive change have been greater than a non-comprehensive? And when you think about that metric longer term, do you assume the trajectory is similar across those 2 buckets or not?

    很好。那再追問一個關於ASP的問題。看起來全面性與非全面性的年對年趨勢不同。你能再解釋一次嗎?為什麼全面性的變動會比非全面性更大?而當你從長期來看這個指標時,你會假設這兩個類別的走勢相似嗎,還是不相似?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes. The biggest change from last year to this year is really around the additional treatment that doctors were providing. So remember, last year, they didn't have as many new patients coming in, but they were still keeping existing patients along in treatment. And it doesn't count as a new case. It really just counts as additional revenue. And therefore, ASPs are higher as a result of that. Conversely, as now they focus more on primary cases and new patients coming in, we see that shift. We saw that shift really started in the third quarter of last year. It's kind of been -- progressed relatively steady from third quarter on. And that's kind of how we think of it. There's not a -- it's not a promotional change or there's nothing of that nature. It's really more just on how we're recognizing revenue between a primary shipment and then an additional treatment that a doctor provides.

    是的。從去年到今年最大的變化,主要在於醫師提供的額外治療增加。所以請記得,去年他們沒有那麼多新病患進來,但仍然讓既有病患持續在療程中。而那不會被算作新的案例。它其實只會被算作額外收入。因此ASP會因此而較高。相反地,現在他們更聚焦在主要病例與新病患進來,我們就看到那樣的轉移。我們看到那個轉移其實在去年第三季就開始了。從第三季之後就——相對穩定地持續進展。我們大致就是這樣看待它。這不是——不是促銷變動,也不是那類事情。它更多是關於我們如何在主要出貨與醫師提供的額外治療之間認列收入。

  • Operator

    Operator

  • Our next question comes from Elizabeth Anderson with Evercore.

    下一個問題來自 Evercore 的 Elizabeth Anderson。

  • Elizabeth Hammell Anderson - MD & Fundamental Research Analyst

    Elizabeth Hammell Anderson - MD & Fundamental Research Analyst

  • So my question is in terms of the second quarter, could you talk about how you saw volumes progressing maybe in the U.S. across the 3 months?

    所以我的問題是,關於第二季,你們能否談談在美國這邊,三個月份的量是如何推進的?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • I think when we look at it -- Elizabeth, this is John. We saw strength across our business. We're not going to get into kind of month by month, but I think what we saw and you saw in the print for the second quarter, very strong across geographies, products and so on. And what we're seeing is a reflection of that with our guidance.

    我想當我們看這件事——Elizabeth,我是John。我們看到整體業務都很強勁。我們不會逐月細談,但我認為你在第二季的公告中看到的,就是在各地區、各產品等方面都非常強勁。而我們的指引也反映了這一點。

  • Elizabeth Hammell Anderson - MD & Fundamental Research Analyst

    Elizabeth Hammell Anderson - MD & Fundamental Research Analyst

  • Okay. That makes sense. And then turning to the cash flow, I appreciate the CapEx increase this year is largely a function of the new facility in Poland. Is that something that should continue on at that kind of pace going forward? Or do you see kind of all of that wrapped up in this year's expense and then we should go back to sort of more normalized levels afterwards?

    好的。這很合理。接著談到現金流,我理解今年資本支出(CapEx)的增加主要是波蘭新廠所致。這樣的支出節奏未來也會持續嗎?還是你們認為大部分都會在今年的支出中完成,之後就會回到較正常的水準?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes. I think what you'll see with kind of the convergence of what we have now, we have a lot of capacity that we're adding to meet the demand in the markets that we have. And we have that unique event with Poland kind of going on from the land purchase, building and equipment that goes in. So this year will be a little bit heavy from that standpoint. And then going forward, it should just be more about the expansion and growth that way but not as much as this year with the building as well.

    是的。我想你會看到,隨著我們目前所做的整合,我們正在增加大量產能,以滿足我們所服務市場的需求。而波蘭這件事是一個比較特殊的事件,從購地、建廠到設備進駐都在進行。所以今年在這方面會比較重。而往後,應該就會更偏向以擴張與成長為主,但不會像今年一樣還包含建廠的比重那麼高。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Elizabeth, this is Joe. When you're thinking about -- we're talking about 200% growth rates, right? And now here, we're talking about growth rates on the upper end of what our revenue models -- we've given to you guys. So it requires capacity and that kind of investment and -- it's a good question. But like John said, we hit it hard this year, built some more capacity, and this will lay in over time.

    Elizabeth,我是Joe。當你在思考——我們談的是200%的成長率,對吧?而現在我們談的是位於我們給各位的營收模型上緣的成長率。所以這需要產能以及那樣的投資——這是個好問題。但就像John說的,我們今年大力投入、建立更多產能,然後這些會隨時間逐步到位。

  • Elizabeth Hammell Anderson - MD & Fundamental Research Analyst

    Elizabeth Hammell Anderson - MD & Fundamental Research Analyst

  • Yes. No. That certainly makes sense especially as you actually filled it ahead of the growth.

    是的。不。這確實很合理,尤其是你們實際上是在成長發生之前就先把產能填滿了。

  • Operator

    Operator

  • Our next question comes from Liza Garcia with Wolfe Research.

    下一個問題來自 Wolfe Research 的 Liza Garcia。

  • Elizabeth Cristina Mari Garcia - Research Analyst

    Elizabeth Cristina Mari Garcia - Research Analyst

  • Can you hear me all right?

    你們聽得到我嗎?

  • Shirley Stacy - VP of Corporate Communications & IR

    Shirley Stacy - VP of Corporate Communications & IR

  • Yes, we can hear you fine.

    是的,我們聽得很清楚。

  • Elizabeth Cristina Mari Garcia - Research Analyst

    Elizabeth Cristina Mari Garcia - Research Analyst

  • So I guess just digging into kind of how you're thinking about the exocad expansion with the Ivoclar Vivadent and kind of how you see the opportunity building there, you've mentioned a couple of things. But also, should we view this kind of as like a first move for exocad and going forward, the strategy into more CAD/CAM?

    那我想更深入了解你們如何看待與 Ivoclar Vivadent 的 exocad 擴張,以及你們如何看那裡的機會在建立中;你們提過幾點。另外,我們是否應該把這視為 exocad 的第一步,未來策略會進一步走向更多CAD/CAM?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes. Liza, it's a good question, right? When you think about -- we talk about the GP segment. We talk about ortho-restorative. And I think most people, if you study this -- that exocad is one of the few companies out there that actually offers a digital type of restorative platform for dentists all around the world. Our vision for our business is we become a big part of restorative in saving enamel and moving teeth. Before you actually do implants, you need to do different things. And that's what -- that, we think, is the revolution of orthodontics because that wasn't a tool that was really used before. And so exocad and iTero plug in really well behind that.

    是的。Liza,這是個好問題,對吧?當你想到——我們談到GP(一般牙科)領域。我們談到正畸-修復(ortho-restorative)。而我想大多數人如果研究這個——exocad是少數真正能為全球牙醫提供數位修復平台的公司之一。我們對業務的願景是:在保留琺瑯質與移動牙齒的修復領域中,成為很重要的一部分。在你真正做植牙之前,你需要做不同的事情。而我們認為那就是正畸的革命,因為以前並沒有真正使用那樣的工具。因此,exocad和iTero在這方面能很好地銜接配合。

  • Never forget that our strategy is always about selling more Invisalign. That's what exocad is about. That's what iTero is about, too. But they also have to have credibility as units in those segments. And that's when we talk about what we're doing with exocad and iTero. We're expanding that technology but always with the thought of how we can be more effective in ortho-restorative. John actually runs the business so I'll let him [talk about that].

    永遠不要忘記,我們的策略始終是賣出更多Invisalign。這就是exocad的核心。iTero也是如此。但它們也必須在各自的細分領域中具備可信度。這也是我們在談我們對exocad與iTero所做的事情時的重點。我們在擴展那項技術,但始終帶著一個想法:我們如何在正畸-修復方面變得更有效率。John實際負責這項業務,所以我讓他[談談那部分]。

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • No, I think you summarized it well. I mean this is a -- it's been just over a year. We're very pleased with how the business stands -- as it stands alone and then the technical and commercial integration that's been going on. And we see more and more synergies and feel good about the digital platform that this helps us move forward. So more to come on this, but after a year, we're very pleased.

    不,我覺得你總結得很好。我的意思是,這才剛超過一年。我們對業務目前的狀況非常滿意——不論是它作為獨立業務的表現,還是一直在進行的技術與商業整合。我們看到越來越多的綜效,也對這個數位平台能幫助我們持續向前推進感到很有信心。所以後續還會有更多進展,但就一年來看,我們非常滿意。

  • Elizabeth Cristina Mari Garcia - Research Analyst

    Elizabeth Cristina Mari Garcia - Research Analyst

  • Great. Awesome. And then I was just wondering if you're hearing any indications from your customers about staffing as a potential issue that's kind of limiting their availability anywhere. It doesn't -- obviously, the report doesn't certainly seem that way, but channel checks have kind of indicated some more limited staffing.

    很好。太棒了。另外我想問的是,你們是否從客戶那邊聽到任何跡象,表示人力配置可能成為一個問題,進而在某些地方限制他們的可用性?顯然,報告看起來並不像是這樣,但通路調查顯示人力似乎更為吃緊。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes. Liza, it's Joe again. I think -- I wouldn't call it a hindrance right now. They have to pay more to find these people. There is concern out there in the sense of how much people have to pay to bring them in, but we haven't had that as an excuse of doctors saying, "I can't do more cases because I can't find staff." It's just harder to spend more time doing it.

    是的。Liza,我是 Joe,再回答一次。我想——我不會把它稱作目前的阻礙。他們必須付更高的薪資才能找到這些人。外界確實有擔憂,主要在於為了把人招進來需要付多少錢,但我們還沒有遇到醫師以「我找不到人手,所以無法做更多病例」作為理由。只是要花更多時間、成本去做這件事變得更困難。

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • The one thing that you do here, and it's just the reality when we talk about some of that seasonality, people take vacations. There's doctors on vacation as well as staff and patients. So they might fall into that bucket as well to limit some of that staff at their offices.

    另外一點是,這裡的現實情況是,當我們談到某些季節性時,人們會去度假。醫師、員工以及病患都會休假。所以他們也可能落在同一類情況,導致診所的人力有所限制。

  • Operator

    Operator

  • Our next question comes from Richard Newitter with SVB Leerink.

    下一個問題來自 SVB Leerink 的 Richard Newitter。

  • Jaime Lynn Morgan - Associate

    Jaime Lynn Morgan - Associate

  • It's Jaime on for Rich. A quick question from me. On teens, obviously, our checks, specifically within the ortho channel, have been very bullish over the last couple of months. And now with it representing greater than 1/3 of total case shift, is it fair to say now that teen adoption is finally hitting that inflection point in the U.S.? And if not, kind of what are some of the things that you think still need to happen to really start to take on this sort of viewpoint?

    我是 Jaime,代 Rich 提問。我有個簡短問題。關於青少年市場,顯然我們的調查——特別是在矯正通路——過去幾個月一直非常樂觀。而現在青少年已占總病例轉移量的三分之一以上,是否可以說青少年採用率在美國終於到達那個拐點?如果不是,你認為還需要發生哪些事情,才能真正開始形成這種觀點?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • It's Joe. Look, this is not a tipping point, as you referred to it. This is -- it's been a ground war actually. And that ground war has basically started with product liability. And obviously, with Invisalign First and mandibular advancement and some of our other innovations that we've had, we've really opened up that segment and made it available to us, too. Now the work is primarily with orthodontists to make them confident that they can service these teens, not just clinically, but from a business standpoint also. That's why our programs like ADAPT and different things, we put it in place.

    我是 Joe。你看,這不是你所說的那種「臨界點」。這其實——一直是一場地面戰。而這場地面戰基本上是從產品責任(風險)開始的。當然,透過 Invisalign First、下顎前移(mandibular advancement)以及我們其他一些創新,我們確實把這個細分市場打開,讓我們也能進入並服務。現在主要的工作是與矯正醫師合作,讓他們有信心能服務這些青少年——不只是臨床面,還包括商業面。這也是為什麼我們推出像 ADAPT 等各種計畫並加以落地。

  • And remember, if -- the war here is not against other clear aligner companies. It's about braces and fixed appliances. And that's what we really have to break through and get done. And honestly, orthodontists just have to be comfortable not clinically but also from a business standpoint. And I feel like we're making progress in educating teens and educating moms but on the other hand, educating orthodontists to how they can properly do this clinically and also be efficient in their practices in doing it. And that's the ground war part. I feel we're well positioned. And obviously, our numbers say we're making progress. But there is -- we're not declaring victory here at all.

    而且要記得,這場戰爭並不是對抗其他隱形矯正器公司。而是關於傳統牙套與固定式矯正器。這才是我們真正必須突破並完成的。坦白說,矯正醫師必須感到自在的不僅是臨床面,也包括商業面。我覺得我們在教育青少年、教育媽媽方面正在取得進展;但另一方面,也在教育矯正醫師如何在臨床上正確執行,同時在診所營運上更有效率地執行。這就是所謂的地面戰。我認為我們的定位很好。而且顯然,從數據來看我們正在取得進展。但我們完全沒有在這裡宣告勝利。

  • Jaime Lynn Morgan - Associate

    Jaime Lynn Morgan - Associate

  • Got it. And then just one follow-up back to kind of some of the more pronounced summer seasonality. If I look back kind of through 2017 through 2019, it seems like you guys have seen anywhere from flat to maybe mid-single-digit sequential improvement. Consensus is currently standing at something that would imply a decline. So is there any reason to be thinking that it shouldn't at least fall within the bounds of 0 -- a flat to mid-single-digit improvement versus what consensus is currently implying, which would be a decline? Just trying to get a better calibration there.

    了解。接著再追問一題,回到夏季季節性更明顯這件事。如果我回頭看 2017 到 2019 年,你們似乎看到的多半是持平到可能中個位數的季增改善。而市場共識目前的預期則暗示會下滑。所以,有沒有任何理由讓我們認為它不應該至少落在 0——也就是持平到中個位數改善的範圍內,而不是像共識目前所暗示的下滑?我只是想更好地校準一下。

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes. Jaime, this is John. Look, we're trying to give you color to the second half kind of because it's implied in our total year, and you can kind of differ what -- kind of infer what that means from third quarter and fourth quarter. But just trying to give you as much color without giving quarterly guidance is all that, that has been.

    是的。Jaime,我是 John。你看,我們試著就下半年提供一些脈絡,因為這其實已隱含在我們全年指引裡,你也可以從中推導——也就是推估第三季和第四季大概代表什麼。但我們只是想在不提供季度指引的前提下,盡可能給你更多資訊,僅此而已。

  • Operator

    Operator

  • Our next question comes from Michael Ryskin with Bank of America.

    下一個問題來自美國銀行(Bank of America)的 Michael Ryskin。

  • Michael Leonidovich Ryskin - Associate

    Michael Leonidovich Ryskin - Associate

  • Congrats on the quarter on the guide raise. I want to ask first on the -- I guess, for John, on the operating margin, especially on non-GAAP side. You had another really good quarter there, and you bumped the guide a little bit, but you're still sort of -- your outlook for the second half still implies a pretty decent step down in operating margins. I'm just wondering what's going on there. Is there any incremental spend that you're budgeting? And just in general, sort of expand on that. Could you talk a little bit about consumer marketing spend? How are those costs trending? How is the return on that going?

    恭喜本季表現以及上調指引。我想先問——我想是問 John——關於營業利益率,特別是非 GAAP 口徑。你們又交出一個非常好的季度,指引也小幅上調,但你們對下半年的展望仍然暗示營業利益率會有相當明顯的下滑。我想了解這背後發生了什麼。你們是否在預算中規劃了任何額外支出?以及更一般地,能否多談談這點?也能否談一下消費者行銷支出?這些成本趨勢如何?投資報酬(回報)表現如何?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes. It's a good question. I mean look, we're very pleased with our op margin that we've seen through the first half. As you noted, it's a very strong performance, a reflection of a lot of the investments that we made and we continue to make to help grow our business. And we look at the second half as continuing these investments to expand from a sales and marketing standpoint. There are some -- these operating costs that we have to be able to grow our business like we have. It reflects those investments, and we're trying to continue to position ourselves so that we continue momentum and be able to start next year with that momentum. So it's really more of a reflection of that. And obviously, as we go through the second half, we'll update on what that means for margin.

    是的。這是個好問題。你看,我們對上半年所看到的營業利益率非常滿意。如你所說,這是非常強勁的表現,也反映了我們已經投入、並且持續投入的許多投資,以協助推動業務成長。而我們看待下半年,是要持續這些投資,從銷售與行銷的角度進一步擴張。我們確實需要承擔一些營運成本,才能像現在這樣推動業務成長。這反映了那些投資,而我們也希望持續把自身定位好,以便延續動能,並能帶著這股動能進入明年。所以這主要就是這方面的反映。當然,隨著我們走過下半年,我們也會更新這對利益率意味著什麼。

  • Michael Leonidovich Ryskin - Associate

    Michael Leonidovich Ryskin - Associate

  • Okay. And then on the gross margin line, again, just on the -- you got the manufacturing facility in China. You're talking about the plant in Poland up in 2022. Could you give us an update, a reminder of sort of how we should think about progression there in terms of shifting some of the manufacturing in there and how that should work its way through the gross margin line? Sort of when do those plants reach more or less full capacity and sort of your work through the ramp-up there?

    好的。接著在毛利率這一行,再問一次——你們在中國有製造工廠。你們也提到波蘭的工廠會在 2022 年啟用。你能否給我們一個更新,並提醒我們應該如何看待那邊的進程:包括把部分製造轉移到那裡,以及這將如何逐步反映到毛利率?也就是說,這些工廠大概何時能達到接近滿載產能,以及你們在爬坡(ramp-up)過程中的推進情況?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes. You're right. When we go live, there is -- until you get that capacity up -- and we're really -- we know how to do that manufacturing. We've learned as we've gone through some of the China facility ramp-up. That will get applied to how we ramp up in Poland. We'll move doctors over kind of country by country and ramp things up. That will happen in the first half of next year, but very mindful of what it means from a margin standpoint and do everything we can to minimize that inefficiency that you have when you first start up and be able to get those facilities up and running at near 100% capacity.

    是的。你說得對。當我們正式上線時,在你把產能拉升到位之前——而且我們確實——我們知道如何進行那樣的製造。我們在中國廠區爬坡的過程中一路學到很多。這些經驗會應用到我們在波蘭的爬坡方式上。我們會以國家為單位逐步把醫師導入並把規模拉起來。這會在明年上半年發生,但我們會非常留意從毛利率角度的影響,並盡一切努力把剛啟動時的低效率降到最低,讓這些設施能以接近 100% 的產能運轉。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes. And one of the things that John knows better than me on this one, Michael, is when we ramped up China, remember, we started with a rental, temporary facility that was not even close to scale, and it just pounded our cost. But we just wanted to get in place, get the workflow done. We built a building next to where that area was then transitioned into it. So that was a pretty big bump that we took there. We're not anticipating, John, like the same.

    是的。而且在這件事上,Michael,有一點 John 比我更清楚:我們當初在中國爬坡時,記得我們先從一個租用的臨時廠房開始,那個規模根本不夠,成本被打得很重。但我們只是想先把據點建立起來,把工作流程跑順。之後我們在那個區域旁邊蓋了一棟新大樓,再轉移進去。所以那時我們承受了一個相當大的衝擊。我們不預期,John,會出現同樣的情況。

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Right. And that would happen, Michael, when -- we kind of quietly went live in Q2 of last year for that new greenfield facility. And it's all about running that factory with a high utilization, have an efficient labor and kind of productivity there that we know how to drive. But there is some ramp-up period, but we'll look to that in kind of the first half and then see improvement as we go into the second half.

    對。而那會發生在——Michael——我們在去年第二季其實低調地讓那座全新綠地(greenfield)廠區上線。重點在於以高稼動率運行工廠,讓人力效率與生產力達到我們知道如何推動的水準。當然會有一段爬坡期,我們會主要在上半年處理,然後在下半年看到逐步改善。

  • Operator

    Operator

  • Our next question comes from Ravi Misra with Berenberg Capital Markets.

    下一個問題來自 Berenberg Capital Markets 的 Ravi Misra。

  • Ravi Misra - Analyst

    Ravi Misra - Analyst

  • So I guess I have 2 questions, 1 more on the R&D side and 1 on China. So just on the R&D, one of your competitors announced a new polymer. And I think one of the things that's actually turned up in our checks with orthos at least is that SmartTrack gives you an edge. Just curious on your view and whether that's kind of starting to have any sort of impact or is it too early and then how you plan to maybe position yourself to kind of keep ahead of the peers.

    我想我有兩個問題,一個偏研發,另一個關於中國。先談研發,你們的一位競爭對手宣布了一種新的聚合物。而且我認為,至少在我們對骨科矯正醫師(orthos)的調查中,SmartTrack 確實讓你們有優勢。想請教你們的看法:這是否開始產生任何影響,還是說現在還太早?以及你們打算如何定位自己,以持續領先同業。

  • And then secondly, just around China, I guess it's another kind of competition question with, I guess, your largest but still relatively small competitor going public. How are you kind of viewing that market now with kind of another, I guess, well-funded competitor out there in terms of the ability to grow the market or kind of go after a potential segment of that market, whether it's the more luxury-focused patients? Or how are you kind of segmenting the population there?

    第二個是關於中國,我想這也是另一個競爭問題:你們最大的、但規模仍相對較小的競爭對手上市了。面對另一個資金更充裕的競爭者,你們現在如何看待這個市場——不論是擴大市場規模的能力,或是切入某個潛在細分市場(例如更偏奢華取向的患者)?你們在那裡是如何做族群分層的?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Ravi, on your first question on the new polymer, remember, we do multilayer materials. So it's various polymers that you put together, and we're balancing the equation between elasticity and overall rigidity or tensile strength. And it's like our other competitors are starting to figure that piece out and see pieces of it. We have strong patents around SmartTrack and obviously improvement over time. It's a real important part about not just having the right materials but having the right kind of system in place, and that's a treatment planning part that we talked about, 25 years of understanding how to really activate those aligners and make that plastic actually work through those algorithms. And we don't use the displacement methodology, which is basically building wire that kind of leads things. It actually engages with these things in a different way.

    Ravi,關於你第一個問題——新的聚合物——請記得我們使用的是多層材料。也就是把各種聚合物組合在一起,並在彈性與整體剛性或抗拉強度之間取得平衡。就像我們其他競爭對手也開始摸索出這一塊,看到其中一些要素。我們在 SmartTrack 上有強而有力的專利,當然也會隨時間持續改良。重點不只是材料要對,還要有正確的整體系統;其中包含我們談到的治療規劃部分——25 年來我們理解如何真正「啟動」這些牙套,並透過演算法讓這種塑料發揮作用。而且我們不採用位移(displacement)方法論,那基本上是用線材去「帶動」移動。我們是以不同方式讓它與這些結構互動。

  • So I expect more companies to come out and work different polymers or whatever. We have a huge amount of experience to that, but don't forget about the entire system, the algorithms, how it works together and how it works with attachments, the exactness of those attachments, where you put those attachments, how they're shaped. There's a lot going on there. We feel good about our position, and we'll continue to innovate in that space across all those spectrums. But there's nothing in the competitive marketplace that we are concerned with that would change the trajectory of where we're investing right now.

    所以我預期會有更多公司推出不同的聚合物或類似材料。我們在這方面有大量經驗,但別忘了整個系統:演算法、各部分如何協同運作,以及它如何與附件(attachments)配合——附件的精準度、附件放置的位置、形狀如何設計。這裡面有很多事情在同時發生。我們對自身的定位很有信心,並會在所有這些面向持續創新。但在競爭市場上,沒有任何事情讓我們擔心到需要改變我們目前投資方向的軌跡。

  • From a China competitive standpoint, obviously, Angelalign IPO, we watch that closely. And it gives some clarity to everybody in that marketplace as they IPO-ed and what's going on. And I think you see they're strong in Tier 3 cities. They're strong with public hospitals in different areas and -- but look, we -- I feel good about our position in China. Our manufacturing is strong. Our training centers there are strong. Our treatment planning is strong. It's close to accounts. We had good growth in the quarter overall, good sequential growth, good year-on-year growth. I like our position there. John, anything?

    從中國的競爭角度來看,Angelalign 的 IPO 我們當然密切關注。他們上市後,市場對於他們的狀況與進展也更清楚了。我想你也看到他們在三線城市很強。他們在不同地區的公立醫院也很強——但你看,我——我對我們在中國的定位感到很有信心。我們的製造能力很強。我們在那裡的培訓中心很強。我們的治療規劃很強。而且貼近客戶。我們本季整體成長不錯,季比季成長不錯,年比年成長也不錯。我喜歡我們在那裡的定位。John,有要補充的嗎?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes. I mean just to add, in China, we've been competing in China with various companies since we've been there. So it's nothing new really with the IPO. It's really more of a reflection of this under-penetrated market in China. China is a huge opportunity for Clear Aligner business. And so we feel very good about our positioning there. Primarily, cases are done with wires and brackets. And so this is less about share shifting amongst clear aligner and more about growth in the category.

    是的。我補充一下,在中國,我們自從進入以來就一直在和各種公司競爭。所以 IPO 其實並沒有什麼新鮮的。它更像是反映出中國這個市場仍然滲透率偏低。中國對透明牙套(Clear Aligner)業務而言是巨大的機會。因此我們對自身在那裡的定位非常有信心。目前主要的病例仍是用鋼絲與托槽完成。所以這與其說是透明牙套之間的市占轉移,不如說是品類本身的成長。

  • Shirley Stacy - VP of Corporate Communications & IR

    Shirley Stacy - VP of Corporate Communications & IR

  • Thanks, Ravi. Yes. Well, listen, thank you, everyone, for joining us today. We really appreciate your time. We look forward to speaking to you at upcoming financial conferences and industry meetings, including the International Dental Show in Cologne, Germany, September 22 through 25, where we'll be showcasing Align, exocad innovations and a hybrid and multimedia exhibition space through physical and virtual experiences. We'll also be hosting an investor meeting in conjunction with our GP Summit in October in Las Vegas in Nevada. We'll have that October 29 and 30. So look for more information. And if you have any additional questions, please follow up with our Investor Relations department. Thanks, and have a great day.

    謝謝你,Ravi。是的。各位,感謝今天加入我們。我們非常感謝各位的時間。我們期待在接下來的財務會議與產業會議上與各位交流,包括 9 月 22 日到 25 日在德國科隆舉辦的國際牙科展(International Dental Show),屆時我們將展示 Align、exocad 的創新,以及一個結合實體與虛擬體驗的混合式多媒體展區。我們也將在 10 月於內華達州拉斯維加斯、配合我們的 GP Summit 舉辦投資人會議。時間是 10 月 29 日與 30 日。請留意後續更多資訊。若各位還有其他問題,請與我們的投資人關係部門聯繫。謝謝,祝各位有美好的一天。

  • Operator

    Operator

  • This concludes today's conference. You may disconnect your lines at this time. Thank you for your participation.

    今天的電話會議到此結束。您現在可以掛斷電話線。感謝您的參與。